Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies

Clinical Cancer Research

Volumn 16, Issue 1, 2010, Pages 11-20

  Campoli, Michael ^a   Ferris, Robert ^b   Ferrone, Soldano ^b   Wang, Xinhui ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; PANITUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; VINCRISTINE;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE IDIOPATHIC THROMBOCYTOPENIA; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CROSS PRESENTATION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EFFECTOR CELL; ERYTHEMA INFECTIOSUM; FEVER; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HOT FLUSH; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOTHYROIDISM; IMMUNOTHERAPY; INDUCED HYPOTENSION; INFECTION; INTESTINE PERFORATION; LARGE CELL LYMPHOMA; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LYMPHOMA; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; URTICARIA; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 74949136580     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2345     Document Type: Review

References (63)

1. Ehrlich P. Collected studies on immunity. New York, NY: J. Wiley & Sons; 1906.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
3. Campoli M, Ferrone S. Immunotherapy of malignant disease: The coming age of therapeutic monoclonal antibodies.. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: Principles & Practice of Oncology. 23. New York, NY: Lippincott Williams and Wilkins; 2009, p. 1-18.
4. Badger C, Anasetti C, Davis J, Berstein I. Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res 1987;6:419-34.
5. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
6. Groner B, Hartmann C, Wels W. Therapeutic antibodies. Curr Mol Med 2004;4:539-47.
7. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
8. Martin EW, Jr., Thurston MO. The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection. Cancer Invest 1996;14:560-71.
9. Hoffman EJ, Tornai MP, Janecek M, Patt BE, Iwanczyk JS. Intraoperative probes and 90 imaging probes. Eur J Nucl Med 1999;26:913-35.
10. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
11. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol 2004;5:539-49.
12. Mohammed AA, Shergill IS, Vandal M, Gujral SS. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn 2007;7:345-9.
13. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007;9:257-88.
14. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-8.
15. Buelow R, Schooten WV. The future of antibody therapy. Immunotherapy in 2020. Berlin, Germany: Springer Berlin Heidelberg; 2007, p. 83-106.
16. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986;83:3825-9.
17. Yang X, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
18. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
19. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11.
20. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
21. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
22. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44.
23. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004;104:1166-73.
24. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005;139:439-46.
25. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36.
26. Ghetie MA, Crank M, Kufert S, Pop I, Vitetta E. Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother 2006;29:536-44.
27. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003;17:604-11.
28. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 2004;6:529-31.
29. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
30. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 2008;100:113-31.
31. Cassard L, Cohen-Solal J, Camilleri-Broët S, et al. Fc γ receptors and cancer. Springer Semin Immunopathol 2006;28:321-8.
32. Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008;8:759-68.
33. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
34. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95.
35. Lopez-Albaitero A, Lee SC, Morgan S, et al. Role of polymorphic Fc ã receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58:1855-64.
36. Zent CS, Secreto CR, LaPlant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849-56.
37. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:411581-7.
38. Coiffi B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-13.
39. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
40. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002;110:71-9.
41. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
42. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fc receptors on dendritic cells. J Exp Med 2002;195:1653-9.
43. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-64.
44. Ma J, Samuel J, Kwon GS, Noujaim AA, Madiyalakan R. Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres. Cancer Immunol Immunother 1998;47:13-20.
45. Zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002;62:2244-7.
46. Akiyama K, Ebihara S, Yada A, et al. Targeting apoptotic tumor cells to FcR provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003;170:1641-8.
47. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007;13:5133-43.
48. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001;13:45-51.
49. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 2008;20:89-95.
50. de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007;26:3594-602.
51. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008;67:93-102.
52. Onyango P. Genomics and cancer. Curr Opin Oncol 2002;14:79-85.
53. Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-95.
54. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 2005;93:189-234.
55. Xue SA, Stauss HJ. Enhancing immune responses for cancer therapy. Cell Mol Immunol 2007;4:173-84.
56. Whiteside T, Campoli M, Ferrone S. Tumor induced immune suppression mechanisms and possible solutions. In: Nagorsen F, Marincola M, editors. Analyzing T Cell Responses. How to analyze cellular immune responses against tumor associated antigens. Netherlands: Springer-Verlag; 2005, p. 43-81.
57. Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009;100:1697-703.
58. Ferrone S. Tumour immune escape. Semin Cancer Biol 2002;12.
59. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
60. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002;110:289-94.
61. Andoniou CE, Coudert JD, Degli-Esposti MA. Killers and beyond: NK-cell-mediated control of immune responses. Eur J Immunol 2008;38:2938-42.
62. Werner H. Tolerance and reactivity of NK cells: two sides of the same coin? Eur J Immunol 2008;38:2930-3.
63. Zimmer J, Andrès E, Hentges F. NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol 2008;38:2942-5.